Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7966 to 7980 of 8941 results

  1. Weight management: lifestyle services for overweight or obese adults (PH53)

    This guideline has been updated and replaced by NICE guideline NG246.

    Withdrawn guideline

  2. Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia (IPG641)

    This guidance has been updated and replaced by HealthTech guidance 639.

    Withdrawn guidance

  3. Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine (IPG559)

    This guidance has been updated and replaced by NICE HealthTech guidance 643.

    Withdrawn guidance

  4. Endoluminal gastroplication for gastro-oesophageal reflux disease (IPG404)

    Interventional procedures, IPG404 - Issued: July 2011 --> This guidance has been updated and replaced by NICE HealthTech guidance 661.

    Withdrawn guidance

  5. Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension (IPG418)

    Interventional procedures, IPG418 - Issued: January 2012 --> This guidance has been updated and replaced by NICE HealthTech guidance 662.

    Withdrawn guidance

  6. Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus (IPG789)

    We have moved interventional procedures guidance 789 to become HealthTech guidance 723. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    This guidance has been updated and replaced by NICE's highly specialised technologies guidance 34.

    Withdrawn guidance

  8. Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA648)

    This guidance has been updated and replaced by NICE technology appraisal guidance on dupilumab for treating severe chronic rhinosinusitis with nasal polyps (TA1134).

    Withdrawn guidance

  9. Kidney conditions: CKD and SGLT2 inhibitors (IND322)

    This indicator has been updated and replaced by NICE indicator 324.

    Withdrawn indicator

  10. Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]

    In development Reference number: GID-TA10745 Expected publication date:  17 July 2024

    Technology appraisal guidance
    In development

  11. Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva in people 5 years and over [ID6678]

    In development Reference number: GID-TA11805 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    Discontinued Reference number: GID-TA11712

    Technology appraisal guidance
    Discontinued

  13. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Discontinued Reference number: GID-TA11396

    Technology appraisal guidance
    Discontinued

  14. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Discontinued Reference number: GID-TA11338

    Technology appraisal guidance
    Discontinued